- Health Conditions
- Events
- Ask a Doctor
- Visit A Doctor
- HCP Portal
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: neuroimmune cytokine
Galderma, a global dermatology company, has received filing acceptances for its breakthrough treatment nemolizumab. The drug is designed to treat prurigo nodularis and moderate-to-severe atopic dermatitis in adolescents and adults. It received regulatory nods from authorities in Australia, Singapore, Switzerland, and the United Kingdom via the Access Consortium framework.
Log In or Register as a healthcare professional to read the full article.
Subscribe to Updates
Subscribe to receive latest health related news from us
Copyright © Medical Channel Asia 2024.
All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.